Innovotech Inc.'s bioFILM PA(TM) Receives Regulatory Approval In Israel
“This is the first approval of bioFILM PA™ outside of Canada and represents an acceptance of the need for a diagnostic capable of testing organisms in a biofilm state,” said Ken Boutilier, President and CEO of Innovotech Inc. “It provides an opportunity for doctors to treat Israeli patients with effective antibiotics that are tailored to their personal chronic infections. These patients have the potential to recover more quickly, while saving the health care system money, and bacteria will have less chance to develop resistance. Biofilms are the cause of virtually all chronic bacterial infections and are notoriously hard to eradicate. Use of biofilm PA™ will result in better treatment choices right from the start."
The current market capacity in Israel for bioFILM PA™ is estimated to be over 3,000 tests per year.
bioFILM PA™ is the first diagnostic test to assist physicians in the selection of the most effective combination antibiotic treatment of patients with biofilm-based Pseudomonas aeruginosa infections.
Based on Innovotech’s proprietary technology, the company is currently developing companion products to bioFILM PA™ to assist physicians in the selection of the most effective antibiotic treatment for infections caused by both gram-positive and gram-negative bacteria. In a biofilm state, these bacteria are responsible for the majority of all chronic bacterial infections.
Pseudomonas aeruginosa is a common bacterium responsible for many hospital acquired infections including ventilator-associated pneumonia and those found in patients with burns and wounds. It is also one of the major causes of lung infections in individuals with Cystic Fibrosis.
Over eighty percent of microbial infections in the body are caused by organisms in a biofilm state. Biofilm infections are known to be up to 1,000 times more resistant to antibiotics than the same organism in a free-floating state, which demonstrates why it is so critical to identify effective treatments early, such as through the bioFILM PA™ test.
About Innovotech Inc.
Innovotech Inc. is a pioneer in the field of biofilm product development, focused on providing innovative and practical solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are responsible for a host of diseases both in human health and agriculture due to their inherent resistance to existing antibiotics and disinfectants. There are currently no antibiotics, disinfectants, diagnostics or regulatory standards designed specifically for biofilm-forming organisms.
Innovotech currently has one commercial product, bioFILM PA™, and one product, Agress®, in advanced stages of development. bioFILM PA™ is the first diagnostic kit to assist physicians in the selection of the most effective combination antibiotic treatment of patients with biofilm-based chronic lung infections and Agress® is a unique, environmentally friendly seed treatment and plant spray designed to protect crops against both bacterial and fungal infections.
About LevPharm Ltd.
LevPharm Ltd. is a privately owned Israeli pharmaceutical company focusing on marketing and distribution of pharmaceuticals and medical devices primarily in the area of pulmonary and CNS diseases Through their long experience in this market, the professionals at LevPharm focus on building relationships with clinicians and institutions nation-wide. LevPharm currently represents international pharmaceutical and medical device firms in Israel and is actively seeking to expand this portfolio .www. levpharm.com
For more information contact:
Amanda Stadel, Communications Officer Innovotech Inc. Phone: (780) 448-0585 ext. 224 Fax: (780) 424-0941 Email: amanda.stadel@innovotech.ca
Amanda Stadel, Communications Officer Innovotech Inc. Phone: (780) 448-0585 ext. 224 Fax: (780) 424-0941 Email: amanda.stadel@innovotech.ca
Connect with us: Website: www.innovotech.ca Blog: www.cf-test.ca Twitter:www.twitter.com/innovotech